Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KMDA
STRONG BUYFLAGKamada Ltd. · Healthcare · Israel · $407M · Avg Vol: $289K/d
Kamada has quality Q64 and value V61, but momentum at M57 misses the all-three-above-60 path with no corroborating filing, so stage one fails.
COMPANY DESCRIPTION
Kamada Ltd. is an Israeli biopharmaceutical company specializing in the development, manufacture, and commercialization of plasma-derived protein therapeutics for rare diseases and serious conditions. The company's competitive moat stems from its expertise in plasma protein purification and its vertically integrated operations, which encompass plasma collection to commercialization of its specialized orphan drug portfolio for niche patient populations.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 129.3M | 142.5M | 161.0M | 180.5M | 11.7% | 181.7M | 194.9M | 212.5M | 8.5% |
| EPS | -0.05 | 0.17 | 0.25 | 0.35 | 43.5% | 0.35 | 0.43 | 0.61 | 32.4% |
| Shares | 44.8M | 57.5M | 57.5M | 57.7M | +28.7% | 57.7M | — | — | — |
| Debt | 20.6M | 8.8M | 11.1M | 11.6M | -17.5% | 11.6M | — | — | — |
| Equity | 176.0M | 244.0M | 259.5M | 269.1M | 15.2% | — | — | — | — |
| Op CF | 28.6M | 4.3M | 47.6M | 25.5M | -3.7% | 25.7M | — | — | — |
| Inv CF | -3.8M | -5.8M | -10.7M | -9.8M | — | — | — | — | — |
| Fin CF | -9.3M | 22.7M | -13.9M | -18.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KMDA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KMDA | Kamada Ltd.(you) | $407M | 83 | STRONG BUY |
| INCR | InterCure Ltd. | $55M | 36 | HOLD |
| TEVAN.MX | Teva Pharmaceutical Industries Limited | $36.7B | 74 | BUY |
| INMD | InMode Ltd. | $872M | 94 | STRONG BUY |
| 1696.HK | Sisram Medical Ltd | $134M | 88 | STRONG BUY |
| CGEN | Compugen Ltd. | $216M | 98 | STRONG BUY |
| BWAY | BrainsWay Ltd. | $641M | 51 | HOLD |
| SLGL | Sol-Gel Technologies Ltd. | $268M | 33 | SELL |
| BVC.L | BATM Advanced Communications Ltd. | $67M | 51 | HOLD |
| DRTS | Alpha Tau Medical Ltd. | $1.1B | 26 | SELL |
Peer medians: ROE -2.9% · P/E 12.6x · Gross margin 26.1%